fda warning letters compounded semaglutide tirzepatide 2025 Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

28.10

★★★★☆4.8 (126)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

20.96

★★★★★4.9 (98)

Report: FDA must enforce rules on compounded GLP-1s

27.91

★★★★★5.0 (157)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

28.14

★★★★★4.7 (84)

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

27.95

★★★★★4.9 (203)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

29.00

★★★★★5.0 (176)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain. The agency recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were

28.03

★★★★★4.8 (132)